Cargando…

Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study

PURPOSE: To investigate the effectiveness and safety of bevacizumab–paclitaxel combination therapy as first- or second-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer in daily clinical practice. METHODS: In this prospective multicenter observational study, bevacizuma...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Yutaka, Yamashiro, Hiroyasu, Toh, Uhi, Kondo, Naoto, Nakamura, Rikiya, Kashiwaba, Masahiro, Takahashi, Masato, Tsugawa, Koichiro, Ishikawa, Takashi, Nakayama, Takahiro, Ohtani, Shoichiro, Takano, Toshimi, Fujisawa, Tomomi, Toyama, Tatsuya, Kawaguchi, Hidetoshi, Mashino, Kojiro, Tanino, Yuichi, Morita, Satoshi, Toi, Masakazu, Ohno, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796874/
https://www.ncbi.nlm.nih.gov/pubmed/32715420
http://dx.doi.org/10.1007/s12282-020-01138-4
Descripción
Sumario:PURPOSE: To investigate the effectiveness and safety of bevacizumab–paclitaxel combination therapy as first- or second-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer in daily clinical practice. METHODS: In this prospective multicenter observational study, bevacizumab–paclitaxel was administered at the discretion of attending physicians. Cohorts A and B had hormone receptor-positive and triple-negative breast cancer (TNBC), respectively. Primary endpoint was overall survival (OS). Multivariate analyses were conducted to identify prognostic factors. RESULTS: Between November 2012 and October 2014, 767 patients were enrolled from 155 institutions across Japan. Effectiveness was analyzed in 754 eligible patients (cohort A, 539; cohort B, 215) and safety in 750 treated patients (median observation period, 19.7 months). Median OS (95% CI) was 21.7 (19.8–23.6) months in eligible patients; 25.2 (22.4–27.4) months and 13.2 (11.3–16.6) months in cohorts A and B, respectively; and 24.4 (21.9–27.2) months and 17.6 (15.2–20.0) months in patients receiving first- and second-line therapy, respectively. Factors affecting OS (hazard ratio 95% CI) were TNBC (1.75, 1.44–2.14), second-line therapy (1.35, 1.13–1.63), ECOG performance status ≥ 1 (1.28, 1.04–1.57), taxane-based chemotherapy (0.65, 0.49–0.86), cancer-related symptoms (0.56, 0.46–0.68), and visceral metastasis (0.52, 0.40–0.66). Incidences of grade ≥ 3 AEs hypertension, neutropenia, peripheral neuropathy, proteinuria, and bleeding were 35.7%, 27.2%, 7.2%, 3.7%, and 0.3%, respectively. CONCLUSIONS: In Japanese clinical practice, combined bevacizumab–paclitaxel was as effective as in previous studies. Factors that independently predicted poor prognosis in the present study are consistent with those identified previously. TRIAL REGISTRATION: Trial no. UMIN000009086. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12282-020-01138-4) contains supplementary material, which is available to authorized users.